JP7721142B2 - Masp-2阻害剤および使用方法 - Google Patents

Masp-2阻害剤および使用方法

Info

Publication number
JP7721142B2
JP7721142B2 JP2022533447A JP2022533447A JP7721142B2 JP 7721142 B2 JP7721142 B2 JP 7721142B2 JP 2022533447 A JP2022533447 A JP 2022533447A JP 2022533447 A JP2022533447 A JP 2022533447A JP 7721142 B2 JP7721142 B2 JP 7721142B2
Authority
JP
Japan
Prior art keywords
substituted
compound
unsubstituted
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504541A5 (cg-RX-API-DMAC7.html
JP2023504541A (ja
Inventor
ニール エス. カッショール
ジェニファー リン ゲージ
サラ レベッカ ゴールドスタイン
ド ヨン クォン
トーマス エル. リトル
マーカス メッツ
フォン スペヒト ペーター クルト ノラート
ジェニファー ツォン
Original Assignee
オメロス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オメロス コーポレーション filed Critical オメロス コーポレーション
Publication of JP2023504541A publication Critical patent/JP2023504541A/ja
Publication of JP2023504541A5 publication Critical patent/JP2023504541A5/ja
Application granted granted Critical
Publication of JP7721142B2 publication Critical patent/JP7721142B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022533447A 2019-12-04 2020-12-04 Masp-2阻害剤および使用方法 Active JP7721142B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943629P 2019-12-04 2019-12-04
US62/943,629 2019-12-04
PCT/US2020/063391 WO2021113698A1 (en) 2019-12-04 2020-12-04 Masp-2 inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2023504541A JP2023504541A (ja) 2023-02-03
JP2023504541A5 JP2023504541A5 (cg-RX-API-DMAC7.html) 2023-10-05
JP7721142B2 true JP7721142B2 (ja) 2025-08-12

Family

ID=74106147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533447A Active JP7721142B2 (ja) 2019-12-04 2020-12-04 Masp-2阻害剤および使用方法

Country Status (6)

Country Link
US (4) US12030853B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069676A1 (cg-RX-API-DMAC7.html)
JP (1) JP7721142B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020395306B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159159A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113698A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
AU2020395306B2 (en) * 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
TWI867422B (zh) 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
JP2014506877A (ja) 2011-01-04 2014-03-20 ノバルティス アーゲー 加齢性黄斑変性症(amd)の処置に有用なインドール化合物またはそのアナログ
JP2017508789A (ja) 2014-02-25 2017-03-30 アキリオン ファーマシューティカルズ,インコーポレーテッド 補体媒介障害の治療のための化合物
WO2019186164A1 (en) 2018-03-29 2019-10-03 University Of Leeds Factor xiia inhibitors
WO2019211585A1 (en) 2018-04-30 2019-11-07 University Of Leeds FACTOR XIIa INHIBITORS
JP2022552048A (ja) 2019-08-21 2022-12-15 カルビスタ・ファーマシューティカルズ・リミテッド 酵素阻害剤

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1082324A4 (en) 1998-05-26 2002-01-02 Merck & Co Inc IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU3192500A (en) 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
HUP0202191A3 (en) 1999-05-19 2003-02-28 Pharmacia Corp Chicago Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US20040072862A1 (en) 1999-06-04 2004-04-15 Bitler Catherine M. Compositions for treating ischemia-related neuronal damage
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
WO2001079195A2 (en) 2000-04-14 2001-10-25 Corvas International, Inc. Pyridine and pyrazine derivatives as thrombin inhibitors
WO2001087851A1 (en) 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
GB0012795D0 (en) 2000-05-25 2000-07-19 Novartis Ag Organic compounds
CO5170524A1 (es) 2000-05-29 2002-06-27 Monsanto Co Arilo policiclico y pirazinonas de heteroarilo sustituidos utiles para la inhibicion selectiva de la cascada de coagulacion
CO5160330A1 (es) 2000-05-30 2002-05-30 Monsanto Co Reemplazo de arilo policiclico y heteroarilo pirimidinonas utiles para la inhibicion selectiva de una coagulacion en cascada
JP2004516286A (ja) 2000-12-18 2004-06-03 メルク エンド カムパニー インコーポレーテッド ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
MXPA04003169A (es) 2001-10-03 2004-07-08 Pharmacia Corp Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion.
CA2462647A1 (en) 2001-10-03 2003-04-10 Michael S. South 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
AU2003299901A1 (en) 2002-10-04 2004-05-04 Merck And Co., Inc. Thrombin inhibitors
US20060128613A1 (en) 2003-03-12 2006-06-15 The Procter & Gamble Company Melanocortin receptor ligands
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US20140056873A1 (en) 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
EP2465534B1 (en) 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DE602006010834D1 (de) 2005-03-16 2010-01-14 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
EP2029553A1 (en) 2006-05-22 2009-03-04 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use as a medicine
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
HUP1000366A2 (en) 2010-07-13 2012-03-28 Mta Enzimologiai Intezet Novel proteins, their production process and use tereof
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
AU2013201779B2 (en) 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
PL2718290T3 (pl) 2011-06-07 2016-11-30 Kompozycje i sposoby modulowania kinazy
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
NZ629675A (en) 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
AR091490A1 (es) 2012-06-19 2015-02-11 Bristol Myers Squibb Co Antagonistas de iap
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
EP2922535B1 (en) 2012-11-20 2021-11-10 Merck Sharp & Dohme Corp. Thrombin inhibitors
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
US20170253667A1 (en) 2016-01-05 2017-09-07 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
NZ745531A (en) 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
US20180105604A1 (en) 2016-10-13 2018-04-19 University Of Leicester Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515729A (ja) 2007-01-10 2010-05-13 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
JP2014506877A (ja) 2011-01-04 2014-03-20 ノバルティス アーゲー 加齢性黄斑変性症(amd)の処置に有用なインドール化合物またはそのアナログ
JP2017508789A (ja) 2014-02-25 2017-03-30 アキリオン ファーマシューティカルズ,インコーポレーテッド 補体媒介障害の治療のための化合物
WO2019186164A1 (en) 2018-03-29 2019-10-03 University Of Leeds Factor xiia inhibitors
WO2019211585A1 (en) 2018-04-30 2019-11-07 University Of Leeds FACTOR XIIa INHIBITORS
JP2022552048A (ja) 2019-08-21 2022-12-15 カルビスタ・ファーマシューティカルズ・リミテッド 酵素阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[online],2011.12.05-2004.09.21, [検索日] 2024.07.31 CAS登録番号 749177-11-5, 1348395-03-8, 1348431-17-3, 1348728-96-0, 1348730-54-0

Also Published As

Publication number Publication date
US20240351980A1 (en) 2024-10-24
US12703684B2 (en) 2026-08-11
US20240317682A1 (en) 2024-09-26
US20250197349A1 (en) 2025-06-19
AU2020395306B2 (en) 2025-04-24
JP2023504541A (ja) 2023-02-03
US12692229B2 (en) 2026-07-28
CA3159159A1 (en) 2021-06-10
AU2020395306A1 (en) 2022-06-30
US12030853B2 (en) 2024-07-09
EP4069676A1 (en) 2022-10-12
US20210171461A1 (en) 2021-06-10
WO2021113698A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US12486278B2 (en) MASP-2 inhibitors and methods of use
JP7721143B2 (ja) Masp-2阻害剤および使用方法
US12030853B2 (en) MASP-2 inhibitors and methods of use
JP7699389B2 (ja) Masp-2阻害剤および使用方法
AU2023266363A1 (en) MASP-2 inhibitors and methods of use
US20240228499A1 (en) Masp-2 inhibitors and methods of use
TW202523310A (zh) Masp-2抑制劑及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230927

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250723

R150 Certificate of patent or registration of utility model

Ref document number: 7721142

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150